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Abstract The angiotensin-I-converting enzyme (ACE) inhibi-
tory activity of a tryptic digest of bovine ß-lactoglobulin (ß-lg) 
was investigated. Intact ß-lg essentially did not inhibit ACE while 
the tryptic digest gave an 84.3% inhibition of ACE. Peptide 
material eluting between 20 and 25% acetonitrile during C1 8 
solid-phase extraction of the ß-lg tryptic digest inhibited ACE by 
93.6%. This solid-phase extraction fraction was shown by mass 
spectroscopy to contain ß-lg f(142-148). This peptide had an 
ACE IC5 0 value of 42.6 urnol/1. The peptide was resistant to 
further digestion with pepsin and was hydrolysed to a very low 
extent with chymotrypsin. The contribution of specific amino 
acid residues within the peptide to ACE inhibitory activity and 
the potential application of this peptide as a nutraceutical is 
discussed. 
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1. Introduction 
Bioactive peptides which function as potent physiological 
regulators can be released during in vivo and in vitro hydrol-
ysis of milk proteins by gastric and/or pancreatic enzymes [1]. 
Peptides which inhibit angiotensin-I-converting enzyme 
(ACE) have been isolated from many different food sources 
[2]. A C E (peptidyldipeptide hydrolase E C 3.4.15.1) has been 
classically associated with the renin-angiotensin system regu-
lating peripheral blood pressure. The enzyme can raise blood 
pressure by converting angiotensin I to the potent vasocon-
strictor angiotensin II. A C E is a multifunctional enzyme 
which also catalyses the degradation of bradykinin, and enke-
phalins [3]. Consequently, A C E inhibitory peptides may exert 
antihypertensive and immunostimulating effects and may in-
crease neurotransmitter activity. 
Several A C E inhibitory peptides have been isolated from 
enzymatic casein hydrolysates [1,2,4]. Only limited studies 
have been carried out on whey protein-derived A C E inhibi-
tors. Albutensin A, a peptide derived from serum albumin, 
was shown to inhibit A C E [5]. Synthetic di- and tetra-peptides 
corresponding to a-lactalbumin (oc-la) and ß-lactoglobulin (ß-
lg) sequences were recently shown to inhibit A C E [6]. 
This study describes the isolation and characterisation of 
the most potent ß-lg-derived A C E inhibitory peptide reported 
to date. 
2. Materials and methods 
2.1. Enzymes and substrates 
Bovine trypsin (TPCK-treated, EC 3.4.21.4 Type XIII, 12700 
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BAEE U/mg protein), bovine chymotrypsin (TLCK-treated, EC 
3.4.21.1 Type II, 40-60 BTEE U/mg protein), porcine pepsin A (EC 
3.4.23.1, 3200^1500 U/mg protein) and ACE (EC 3.4.15.1, from rab-
bit lung tissue) were obtained from Sigma Chemical Co. Poole, Dor-
set, UK. 
An enriched fraction of ß-lg (89.8% (w/w) ß-lg) was received as a 
gift from Dr. R. Mehra [7]. 
The ß-lg peptide, Ala-Leu-Pro-Met-His-Ile-Arg corresponding to 
f(142—148) was synthesised using Fmoc solid-phase synthesis at Bio-
Research Ireland, University College Cork, Ireland. Plasma desorp-
tion mass spectroscopy (PDMS), which was carried out at the Bio-
chemistry Department, University of Nottingham, UK, was used to 
determine peptide masses and to confirm peptide purity. 
Hippuryl-L-histidyl-L-leucine and Captopril were from Sigma 
Chemical Co. Poole, Dorset, UK. 
All other reagents were of analytical grade unless otherwise speci-
fied. 
2.2. Laboratory scale hydrolysis of ß-lg with trypsin 
A 25 ml solution of the ß-lg substrate, 8% (w/v) protein, was hydro-
lysed with trypsin at 50°C and pH 8.0 for 240 min. The pH was 
maintained constant using a pH-stat (Metrohm Ltd., Herisau, Swit-
zerland). Following hydrolysis, trypsin was inactivated by heating at 
80°C for 20 min, the hydrolysate was then cooled and stored at 
—20°C for further analysis. Details for the calculation of degree of 
hydrolysis (DH) were given previously [8], The enzyme/substrate ratio 
(E:S), 0.003, was calculated on the basis of total protein content in the 
enzyme and substrate. 
2.3. Treatment of $-lg f( 142-148) with pepsin and chymotrypsin 
The synthetic ß-lg peptide corresponding to residues 142-148, i.e. 
Ala-Leu-Pro-Met-His-Ile-Arg, was incubated separately with chy-
motrypsin and pepsin. For each reaction, 500 ul of enzymatic solution 
(0.1 mg/ml) was added to 500 (il of peptide solution (6 mg/ml), mixed 
and incubated at 50°C for 45 min. Enzymes were inactivated as above. 
Chymotrypsin reactions were buffered using 20 mmol/1 Tris-HCl, pH 
8.0, while the pepsin reactions were carried out in 0.1 mol/1 HC1, pH 
3.0. Separate controls containing peptide, pepsin or chymotrypsin 
were treated in the same manner as the test sample. The E:S ratio 
was 1:60. Acid-washed glassware was used throughout. 
2.4. Fractionation of hydrolysate peptides by solid-phase extraction 
One milliliter of the tryptic digest of the ß-lg enriched substrate (80 
mg/ml protein) was applied to the Cig Bond Elut column. Bond Elut® 
Cía solid-phase extraction columns (2.8 ml) were from Varían Sample 
Preparation Products (Harbour City, CA). Peptide material was 
slowly eluted from this column by stepwise elution (2.8 ml) with in-
creasing concentrations of acetonitrile (ACN) in trifluoroacetic acid 
(TFA, 0.1% (v/v)). 
2.5. Reversed-phase high performance liquid chromatography of solid-
phase extraction fractions 
Reversed-phase (RP) HPLC was performed on a Phenomenex (Phe-
nomenex Ltd., Macclesfield, Chesire, UK) Cig column (250X3.2 mm, 
5 (tm), equilibrated with solvent A (0.1% TFA in H20) and elution 
was with a linear gradient to 80% solvent B (60% acetonitrile, 40% 
H 2 0 , 0.1%, TFA) during the first 50 min, to 90% in the next 10 min, 
to 100% in the next 5 min and the column was re-equilibrated at 100% 
solvent A for the last 20 min. Runs were conducted at room temper-
ature using a Shimazu® HPLC system (Shimadzu Corp., Analytical 
Instruments, Nakagyo-ku, Kyoto, Japan), the flowrate was 0.30 ml 
min - 1 . The injection volume was 5 ul. 
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2.6. Characterisation of ACE inhibition 
ACE inhibitory activity was measured spectrophotometrically using 
hippuryl-L-histidyl-L-leucine as the substrate for ACE [9]. Initial 
screening of ß-lg hydrolysates was carried out using a single assay 
to give an index of ACE inhibition. In general, 50 ul of a 10 mg/ml 
solution of hydrolysate was taken to screen for ACE inhibitory activ-
ity. The IC50 value was expressed in terms of milligrams of freeze-
dried hydrolysate per litre. The % inhibition versus Logio [hydroly-
sate] (mg/1) curves or the % inhibition versus Logio [peptide] (umol/1) 
curves, in the case of synthesised peptide, were constructed using at 
least seven separate analyses. 
3. Results and discussion 
The tryptic hydrolysate of the enriched fraction of ß-lg, 
which had a DH value of 6.52%, gave an ACE inhibition 
index of 84.3%. Unhydrolysed ß-lg gave an ACE inhibition 
index value less than 10% (Table 1). Hydrolysis is therefore 
necessary in order to release ACE inhibitory activity/peptides 
from within the sequence of ß-lg. The peptide material eluting 
between 20 and 25% ACN from the solid-phase extraction of 
the tryptic hydrolysate of ß-lg, having an ACE inhibition in-
dex of 93.6% and an IC50 value of 159.8 mg/1, was analysed 
using mass spectroscopy. From the mass spectroscopy profile 
in Fig. 1A it is seen that this fraction mainly contains a pep-
tide giving a charge to mass ratio of 838.4. This approximates 
very well with the theoretical mass i.e. 837.05 of f(142—148) 
corresponding to peptide 17 formed during the tryptic diges-
tion of bovine ß-lg. This peptide, f(142—148), was synthesised 
and shown to have a charge/mass ratio of 836.4 (Fig. IB). 
This synthetic peptide had an IC50 value of 42.6 umol/1 (Table 
1). To our knowledge, this is the most potent ß-lg-derived 
ACE inhibitory peptide reported to date. Tyr-Leu, a peptide 
derivative of ß-lactorphin (ß-lg f(102-105)) had an IC50 of 
122.1 umol/1 [6]. The IC50 value obtained for Captopril (D-
3-mercapto-2-methylpropyl-L-proline) was in accordance with 
that reported previously (Table 1) [10]. 
Much speculation has taken place as to the contribution of 
specific amino acid residues/sequences to ACE inhibitory po-
tency. Peptides containing hydrophobic amino acids at the 
three C-terminal positions are reported to be potent ACE 
inhibitors [11,12]. Furthermore, structure-activity data sug-
gests that a positive charge, as on the guanidino group of 
the C-terminal Arg, contributes substantially to the ACE in-
hibitory potency of several peptides [13]. The sequence of ß-lg 
f(142-148) appears to reflect these observations. However, the 
C-terminal tripeptide His-Ile-Arg f( 146-148) gave an IC50 
value of 953.5 umol/1 and an IC50 value of 695.5 umol/1 was 
reported for the related Ile-Arg dipeptide [6]. In common with 
several food protein-derived ACE inhibitory peptides, ß-lg 
f(142—148) contains a proline residue. Proline residues were 
« 1R0Q. 
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Fig. 1. Mass spectroscopy profiles of (A) peptide material eluting 
between 20 and 25% acetonitrile following Ci8 solid-phase extrac-
tion of a tryptic digest of ß-lactoglobulin and (B) of synthetic pep-
tide corresponding to ß-lactoglobulin f(142—148). 
suggested to contribute to the potency of ACE-inhibitory pep-
tides from food protein sources [12,14,15]. It may well be that 
the C-terminal (arginine residue) in addition to an internal 
proline residue contribute significantly to the potency of 
ACE inhibitory peptides. It was not possible to obtain the 
Ala-Leu-Pro-Met tetrapeptide using Fmoc synthesis. 
In order for peptides to exert a physiological effect, they 
must interact with ACE at various sites around the body. One 
of the first requirements for this physiological effect is that 
inhibitory peptides should be resistant to further attack by 
digestive proteinases. The synthetic ß-lg f(142-148), shown 
to be present in a tryptic digest of ß-lg, was incubated in 
the presence of pepsin and chymotrypsin in order to investi-
gate the possible formation of further hydrolysis products. 
The RP-HPLC profiles obtained following incubation of ß-
lg f(142 148) with pepsin and chymotrypsin are given in Fig. 
2. 
It appeared from RP-HPLC analysis that no hydrolysis of 
f(142—148) occurred following incubation with pepsin (Fig. 
2a,d,e). RP-HPLC profiles indicate that a low level of hydrol-
ysis occurred following incubation of f(142—148) with chymo-
trypsin (Fig. 2a,b,c). The low degree of hydrolysis was indi-
cated by two 'extra' peaks in the peptide profile (Fig. 2c). 
However, the intensity of the peaks corresponding to the syn-
thetic peptide changed only slightly, indicating a low degree of 
chymotryptic hydrolysis of f(142—148). The tryptic peptide 
Ala-Leu-Pro-Met-His-Ile-Arg has sites which are poten-
Table 1 
ACE inhibitory activity of ß-lactoglobulin-derived tryptic hydrolysate/peptide 
Sample/peptide sequence ACE Inhibition Index 
(%) 
IC50
a 
(umol/1) 
Unhydrolysed ß-lg 
Unfractionated ß-lg hydrolysate 
20-25% ACN peptide elution 
Ala-Leu-Pro-Met-His-Ile-Arg0 
Captopril 
9.6 
84.3 
93.6 159.8b 
42.6 
0.006 
a IC 50 is defined as that amount of peptide which causes 50% inhibition of ACE using hippuryl-histidyl-leucine as substrate. 
b Expressed in mg/1. 
- , Not determined. 
c Corresponding to synthetic ß-lg f(142—148). 
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Fig. 2. RP-HPLC (Cis) profiles detected at 214 nm of (a) peptide 
f(142—148) of ß-lactoglobulin, (b) chymotrypsin control, (c) peptide 
incubated with chymotrypsin, (d) pepsin control, and (e) peptide in-
cubated with pepsin. Acetonitrile gradient conditions are detailed in 
Section 2. 
tially susceptible to hydrolysis by chymotrypsin. However, it 
would be expected that the peptide is too short (i.e. 7 amino 
acid residues) for further hydrolytic action by endoprotein-
ases. Furthermore, reaction conditions with the high E:S ratio 
of 1:60 may have forced the limited hydrolysis of f(142—148) 
by chymotrypsin. It is known that food-derived bioactive pep-
tides are often resistant to further degradation by gastric or 
pancreatic proteinases. 
The whey protein-derived hydrolysate/peptide reported here 
does not have the potency of Captopril (IC5o = 0.006 umol/1), 
a drug commonly used in the treatment of hypertension [10]. 
However, the IC50 values found for the whey protein hydro-
lysate/peptide in this study are comparable to those found for 
casein hydrolysates/peptides shown to have an in vivo antihy-
pertensive effect following oral ingestión by rats [16]. Further-
more, following a study on the oral administration of a tryptic 
casein hydrolysate to normotensive and hypertensive human 
volunteers it has been reported that food-derived peptides 
having IC50 values within the 100-500 u.mol/1 range had po-
tential significant physiological effects as antihypertensive 
agents [17]. It is possible therefore that the ß-lg hydrolysate/ 
peptide reported herein could find application as nutraceuti-
cals in the prevention of hypertension. A nutraceutical has 
been defined as a food or part of a food which provides 
medical or health benefits, including the prevention and treat-
ment of disease [18]. There is an obvious need to perform 
clinical studies with human volunteers on the potential anti-
hypertensive effect of whey protein-derived hydrolysates/pep-
tides before considering the exploitation of these peptides in 
physiologically functional foods. 
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